Published in Cancer Weekly, June 17th, 2008
Previous research with MCP has shown it to be effective in slowing the progression, metastasis and angiogenesis of several types of cancer. Now with further improvement in the modification process, more of the effective substance can be utilized by the body. The first human study described below was done with patients with late...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.